Liquid biopsies, in particular, analysis of cell-free DNA (cfDNA), have emerged as a
promising noninvasive diagnostic approach in oncology. Abnormal distribution of DNA …

Robust and clinically convenient biomarkers for cancer diagnosis, early detection, and
prognosis have great potential to improve patient survival and are the key to precision …

Tumor-derived circulating cell-free DNA (cfDNA) provides critical clues for cancer early
diagnosis, yet it often suffers from low sensitivity. Here, we present a cancer early diagnosis …

Cell‐free DNA (cfDNA) is present in the circulating plasma and other body fluids and is
known to originate mainly from apoptotic cells. Here, we provide the first in vivo evidence of …

Environmental DNA (eDNA) approaches contributing to species identifications are quickly
becoming the new norm in biomonitoring and ecosystem assessments. Yet, information …

Detecting cancer signals in cell-free DNA (cfDNA) high-throughput sequencing data is
emerging as a novel noninvasive cancer detection method. Due to the high cost of …

In the analysis of high-throughput data from complex samples, cell composition is an
important factor that needs to be accounted for. Except for a limited number of tissues with …

Analysis of circulating nucleic acids in bodily fluids, referred to as “liquid biopsies”, is rapidly
gaining prominence. Studies have shown that cell-free DNA (cfDNA) has great potential in …

Simple yet powerful clustered regularly-interspaced short palindromic repeats (CRISPR)
technology has led to the advent of numerous developments in life sciences, biotechnology …

Detection of cellular changes in tissue biopsies has been the basis for cancer diagnostics.
However, tissue biopsies are invasive and limited by inaccuracies due to sampling …